# The Influence of PAR 1 and Endothelin 1 on the Course of Specific Kidney Diseases

**Authors:** Maciej Szymczak, Marcelina Żabińska, Katarzyna Kościelska-Kasprzak, Dorota Bartoszek, Harald Heidecke, Kai Schulze-Forster, Łucja Janek, Krzysztof Kujawa, Jakub Wronowicz, Karolina Marek-Bukowiec, Tomasz Gołębiowski, Mirosław Banasik

PMC · DOI: 10.3390/jcm15010221 · Journal of Clinical Medicine · 2025-12-27

## TL;DR

This study explores how PAR 1 and endothelin 1 levels relate to kidney disease progression and clinical outcomes in various kidney conditions.

## Contribution

The study identifies elevated PAR 1 and endothelin 1 levels in specific kidney diseases and their correlations with clinical markers.

## Key findings

- PAR 1 levels were higher in patients with membranous nephropathy, FSGS, IgA nephropathy, CKD, and hemodialysis compared to healthy controls.
- PAR 1 and endothelin 1 correlated with clinical markers like total protein, albumin, and creatinine in various kidney diseases.
- Anti-PAR1 and anti-ETAR evaluations showed correlations with disease-specific markers.

## Abstract

Background: PAR 1 (protease-activated receptor 1) and endothelin 1 are biomarkers that could be of significance in kidney diseases. Methods: We measured the plasma levels of PAR1 and endothelin 1 in patients with membranous nephropathy (n = 19), focal and segmental glomerulosclerosis (FSGS) (n = 30), systemic lupus erythematosus (SLE) (n = 22), IgA nephropathy (n = 16), mesangial proliferative (non-IgA) glomerulonephritis (n = 7), chronic kidney disease (CKD) (n = 27), and hemodialysis (n = 26), as well as a healthy control group (n = 22). Then, for two years, we tracked the patients’ clinical progress (creatinine, total protein, and albumin levels) and compared the outcomes with their initial PAR 1 and endothelin 1 levels. Moreover, we checked the correlations between PAR 1 and endothelin 1 and the results of anti-PAR1 and anti-ETAR (endothelin A receptor) evaluations. Results: Membranous nephropathy, FSGS, IgA nephropathy, CKD, and hemodialysis patients had higher PAR 1 levels than the control group. PAR 1 correlated with total protein, albumin in SLE, total protein in IgA nephropathy, and creatinine in CKD. Endothelin 1 correlated with albumin in membranous nephropathy, total protein, albumin, creatinine in FSGS, total protein in IgA nephropathy, total protein, and albumin in CKD. PAR 1 correlated with anti-PAR 1 in FSGS. Anti-ETAR correlated with anti-PAR 1 in membranous nephropathy, FSGS, and IgA nephropathy. Conclusions: PAR 1 levels are elevated in some kidney diseases compared to the healthy population. Both PAR 1 and endothelin 1 are supposed to be related to the clinical course of specific kidney diseases.

## Linked entities

- **Proteins:** MARK2 (microtubule affinity regulating kinase 2)
- **Diseases:** membranous nephropathy (MONDO:0005376), systemic lupus erythematosus (MONDO:0007915), IgA nephropathy (MONDO:0005342), mesangial proliferative glomerulonephritis (MONDO:0003139), chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, F2R (coagulation factor II thrombin receptor) [NCBI Gene 2149] {aka CF2R, HTR, PAR-1, PAR1, TR}, EDNRA (endothelin receptor type A) [NCBI Gene 1909] {aka ET-A, ETA, ETA-R, ETAR, ETRA, MFDA}, EDN1 (endothelin 1) [NCBI Gene 1906] {aka ARCND3, ET1, HDLCQ7, PPET1, QME}
- **Diseases:** IgA nephropathy (MESH:D005922), CKD (MESH:D051436), Membranous nephropathy (MESH:D015433), FSGS (MESH:D005923), Kidney Diseases (MESH:D007674), mesangial proliferative (non-IgA) glomerulonephritis (MESH:D017098), SLE (MESH:D008180)
- **Chemicals:** creatinine (MESH:D003404)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12786784/full.md

## Figures

33 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12786784/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12786784/full.md

---
Source: https://tomesphere.com/paper/PMC12786784